{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T21:39:24Z","timestamp":1781386764269,"version":"3.54.1"},"reference-count":33,"publisher":"Wiley","issue":"9-10","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":449,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2000,10,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>A double\u2010blind randomized comparative phase II study of flutrimazole site\u2010release<jats:sup>\u00ae<\/jats:sup> vaginal cream (1, 2 and 4%) with placebo site\u2010release<jats:sup>\u00ae<\/jats:sup> vaginal cream was undertaken in patients with acute vulvovaginal candidosis. Vaginitis was demonstrated by both positive findings on microscopic examination of vaginal smears and positive culture as well as by the presence of clinical signs and symptoms. The vaginal monodose treatment was inserted in the evening at bedtime using a vaginal applicator and, in addition, all four groups of patients received additional topical external cream for application to the vulva twice\u2010daily for 7\u2003days; the placebo group received a placebo cream and the active therapy groups all received a 2% flutrimazole cream. A total of 133 patients who were seen over a 10\u2010month period were screened and randomized: five patients did not take the allocated medication, and four patients whose menstrual period began shortly after study entry were excluded from the study, leaving 124 patients who were randomly allocated to receive a monodose vaginal 1% cream (regimen A, 28 patients), a monodose vaginal 2% cream (regimen B, 32 patients), a monodose vaginal 4% cream (regimen C, 31 patients) or a monodose vaginal placebo cream (regimen D, 33 patients). At the assessment 9\u2003days after the end of therapy the proportion of patients who were cured was 82% in group A, 87.4% in group B, 83.8% in group C and 63.5% in group D. Three patients (10.7%) in group A, four (12.5%) in group B, one (3.2%) in group C and 12 (36.36%) in group D did not respond to the treatment. One patient (3.5%) in group A, and two patients (6.4%) in group C terminated the treatment prematurely due to intolerance. There was a significant association between <jats:italic>Candida<\/jats:italic><jats:italic>glabrata<\/jats:italic> and treatment failure (<jats:italic>P<\/jats:italic>&lt;0.04) and <jats:italic>C. glabrata<\/jats:italic> and carrier state (<jats:italic>P<\/jats:italic>=0.01) in vagina (\u03c7<jats:sup>2<\/jats:sup> test, <jats:italic>P<\/jats:italic>=0.01) and vulvovagina (\u03c7<jats:sup>2<\/jats:sup> test, <jats:italic>P<\/jats:italic>=0.00001). At the assessment 4\u2003weeks after the end of therapy the proportion of cured patients was 60.6% in group A, 78% in group B, 80.6% in group C and 48.4% in group D. Group D (placebo) versus group B (2%) and group C (4%) showed a significant difference (<jats:italic>P<\/jats:italic>=0.01 and <jats:italic>P<\/jats:italic>=0.007, respectively). Although there were no significant differences in clinical and mycological activity between the three active groups, group B (flutrimazole 2% site\u2010release<jats:sup>\u00ae<\/jats:sup> vaginal cream) was chosen for clinical use due to its tolerance profile. Seven patients (25%) in group A, three (9.3%) in group B, two (6.4%) in group C and five (15.1%) in group D relapsed 4\u2003weeks after the end of therapy; the relapse rate was not significantly associated with positive culture results 9\u2003days after treatment. There was a significant association between <jats:italic>C. glabrata<\/jats:italic> and the carrier state (<jats:italic>P<\/jats:italic>&lt;0.01). The overall ineffective treatment (includes failures at control 1, relapses at control 2 and premature terminations) was 39% in group A, 21.7% in group B, 16% in group C and 51.3% in group D. There was a significant difference in the overall ineffective treatment when C and D groups were compared with placebo (<jats:italic>P<\/jats:italic>=0.01 and <jats:italic>P<\/jats:italic>=0.003, respectively).<\/jats:p>","DOI":"10.1046\/j.1439-0507.2000.00575.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T14:47:56Z","timestamp":1047480476000},"page":"355-365","source":"Crossref","is-referenced-by-count":11,"title":["Double\u2010blind randomized dose\u2010finding study in acute vulvovaginal candidosis. Comparison of flutrimazole site\u2010release<sup><b>\u00ae<\/b><\/sup> cream (1, 2 and 4%) with placebo site\u2010release<sup><b>\u00ae<\/b><\/sup> vaginal cream"],"prefix":"10.1111","volume":"43","author":[{"given":"Amalia del","family":"Palacio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracia","family":"S\u00e1nchez\u2010Alor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda\u2010Teresa","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia","family":"Boncompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Alguer\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"G\u00f3mez de la C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"F. C.Odds1988Candidosis of the genitalia. In: Odds F. C. (ed.) Candida and Candidosis 2nd edn. London: Bailliere Tindall pp.\u2003124135"},{"key":"e_1_2_5_3_2","first-page":"44","article-title":"Update on treatment of vulvovaginal candidiasis.","volume":"13","author":"Sobel J. D.","year":"1996","journal-title":"Rev. Iberoam. Micol."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.Supplement_1.S148"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1358\/dof.1990.015.09.143943"},{"key":"e_1_2_5_6_2","first-page":"836","article-title":"In vitro and in vivo activity studies with antifungal activity.","volume":"42","author":"Garc\u00eda\u2010Rafanell J.","year":"1992","journal-title":"Arzneim. Forsch. Drug. Res."},{"key":"e_1_2_5_7_2","first-page":"117","article-title":"In vitro activity of flutrimazole against Candida species and other medically important yeasts.","volume":"10","author":"Burgos A.","year":"1993","journal-title":"Rev. Iberoam. Micol."},{"key":"e_1_2_5_8_2","first-page":"34","article-title":"Microdilution susceptibility for Candida, dermatophytes and moulds using flutrimazole and clotrimazole.","volume":"4","author":"Carrillo\u2010Mu\u00f1oz A. J.","year":"1994","journal-title":"J. Micol. Med."},{"key":"e_1_2_5_9_2","first-page":"832","article-title":"Synthesis and antifungal activity of a series of difluorotritylimidazoles.","volume":"42","author":"Bartrol\u00ed J.","year":"1992","journal-title":"Arzneim. Forsch. Drug. Res."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02263500"},{"key":"e_1_2_5_11_2","unstructured":"P.Duch\u00eane J. P.Laneury P.Papalexiou et\u2003al.1993Pharmacokinetic study after vaginal administration of 14C\u2010flutrimazole in the human.Eur. J. Drug. Metab. Pharmacol. (Special issue)9498"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0926-9959(95)96474-M"},{"key":"e_1_2_5_13_2","first-page":"512","article-title":"Absorption and excretion of radioactivity after intravaginal administration of an advanced delivery system of 14C\u2010flutrimazole vaginal cream to postmenopausal women.","volume":"48","author":"John B.","year":"1998","journal-title":"Arzneim. Forsch. Drug. Res."},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1128\/jcm.32.8.1923-1929.1994","article-title":"Chromagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species.","volume":"32","author":"Odds F. C.","year":"1994","journal-title":"J. Clin. Microbiol."},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/jcm.29.2.297-301.1991","article-title":"Reliability of diagnosing bacterial vaginosis is improved by a standarized method of gram stain interpretation.","volume":"29","author":"Nugent R.","year":"1991","journal-title":"J. Clin. Microbiol."},{"key":"e_1_2_5_16_2","first-page":"666","article-title":"La technique du carr\u00e9 du tapis, m\u00e9thode simple de pr\u00e9tevement dans les mycoses superficielles.","volume":"113","author":"Mariat F.","year":"1967","journal-title":"Ann. Inst. Pasteur."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058701500508"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998509109628"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1991.tb00624.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.1.89"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102500602"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)91490-0"},{"key":"e_1_2_5_23_2","first-page":"148","article-title":"Single\u2010dose 500\u2003mg clotrimazole vaginal tablets compared with placebo in the treatment of Candida vaginitis.","volume":"31","author":"Bro F.","year":"1990","journal-title":"J. Farm. Pract."},{"key":"e_1_2_5_24_2","first-page":"60","article-title":"Butoconazole vaginal inserts for vulvovaginal candidiasis: comparison to clotrimazole.","volume":"2","author":"Brown Jr D.","year":"1985","journal-title":"Adv. Ther."},{"key":"e_1_2_5_25_2","first-page":"992","article-title":"Terconazole for the treatment of vulvovaginal candidiasis.","volume":"35","author":"Thomason J. L.","year":"1990","journal-title":"J. Reproduct. Med."},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1989.tb02243.x"},{"key":"e_1_2_5_27_2","first-page":"1045","article-title":"Butoconazole vaginal cream in the treatment of vulvovaginal candidiasis.","volume":"11","author":"Brown D.","year":"1986","journal-title":"J. Reproduct. Med."},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(85)80007-7"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(98)80001-X"},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jama.1984.03340290034016","article-title":"Establishing the cause of symptoms in women in a family practice.","volume":"251","author":"Berg A. O.","year":"1984","journal-title":"JAMA."},{"key":"e_1_2_5_31_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/CMR.12.1.80","article-title":"Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.","volume":"12","author":"Fidel P. L.","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01964051"},{"key":"e_1_2_5_33_2","first-page":"112","article-title":"Management of persistant vulvovaginal candidosis due to azole\u2010resistant Candida glabrata.","volume":"69","author":"White D. J.","year":"1993","journal-title":"Genitourin. Med."},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/24.4.649"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1439-0507.2000.00575.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1439-0507.2000.00575.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T18:03:01Z","timestamp":1693591381000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1439-0507.2000.00575.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10,2]]},"references-count":33,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2000,10,2]]}},"alternative-id":["10.1046\/j.1439-0507.2000.00575.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1439-0507.2000.00575.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,10,2]]}}}